A Phase 1, Open-label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies.
Prostate | Phase I
What is the purpose of this trial?
This is a first in human, dose escalation study and will assess the safety and tolerability of ARV 110 in men with mCRPC who have progressed on at least 2 prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
- Ages18 years and older
- GenderMale only
- Trial withArvinas Estrogen Receptor, Inc.
- Start Date06/01/2022
- End Date02/28/2023
- Last Updated06/22/2022
- Study HIC#2000024729